Background Doravirine (DOR) is a newly approved antiretroviral belonging to the class of non-nucleoside reverse transcriptase inhibitors (NNRTI), well tolerated and leading to an improved lipid profile in antiretroviral experienced people living with HIV (PLWH). We aimed to evaluate the lipid profile and body mass index (BMI) in experienced people with HIV starting therapy with two DOR-based regimens dolutegravir (DTG)/DOR or lamivudine (3TC)/tenofovir disoproxilfumarato (TDF)/DOR. Data were compared with those obtained from a third group treated with emtricitabine (FTC)/tenofovir alafenamide (TAF)/bictegravir (BIC).
LIPIDS, WEIGHT GAIN AND BODY MASS INDEX IN ARV EXPERIENCED PLWH TREATED WITH DORAVIRINEBASED TREATMENTS: A COMPARISON BETWEEN DUAL OR TRIPLE REGIMENS VS BICTEGRAVIR BASED TRIPLE REGIMEN
GF Pellicanò;
2024-01-01
Abstract
Background Doravirine (DOR) is a newly approved antiretroviral belonging to the class of non-nucleoside reverse transcriptase inhibitors (NNRTI), well tolerated and leading to an improved lipid profile in antiretroviral experienced people living with HIV (PLWH). We aimed to evaluate the lipid profile and body mass index (BMI) in experienced people with HIV starting therapy with two DOR-based regimens dolutegravir (DTG)/DOR or lamivudine (3TC)/tenofovir disoproxilfumarato (TDF)/DOR. Data were compared with those obtained from a third group treated with emtricitabine (FTC)/tenofovir alafenamide (TAF)/bictegravir (BIC).File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
